A possible role for propranolol in the treatment of renal osteodystrophy.
The effect of propranolol upon parathyroid hormone (P.T.H) concentrations was investigated in patients undergoing chronic haemodialysis. 9 patients receiving propranolol for the treatment of hypertension or angina pectoris were compared with 25 similar patients not taking the drug. P.T.H. and alkaline phosphatase concentrations were lower in patients receiving propranolol and there was less radiological evidence of renal osteodystrophy in these patients. Prospective studies are needed to determine whether propranolol may be helpful as an adjunct to other therapy in reversing or preventing renal osteodystrophy.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D002118:Calcium / Q000097:blood; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006961:Hyperparathyroidism / Q000150:complications; D007676:Kidney Failure, Chronic / Q000150:complications; D008274:Magnesium / Q000097:blood; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000037:antagonists & inhibitors / Q000097:blood; D010710:Phosphates / Q000097:blood; D011433:Propranolol / Q000627:therapeutic use*; D006435:Renal Dialysis; D012709:Serum Albumin / Q000032:analysis
D010281:Parathyroid Hormone; D010710:Phosphates; D012709:Serum Albumin; D011433:Propranolol; D000469:Alkaline Phosphatase; D008274:Magnesium; D002118:Calcium